Compare Revolution Medicines Inc. Common Stock (RVMD) vs Americas Gold and Silver Corporation Common Shares no par value (USAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revolution Medicines Inc. Common Stock vs Americas Gold and Silver Corporation Common Shares no par value — how do they compare? Revolution Medicines Inc. Common Stock trades at $193.15 (market cap $40.39B), while Americas Gold and Silver Corporation Common Shares no par value trades at $3.76 (market cap $1.36B). The key difference: Revolution Medicines Inc. Common Stock is far larger — about 29.7× Americas Gold and Silver Corporation Common Shares no par value's market cap, and Revolution Medicines Inc. Common Stock is trading nearer its 52-week high, Americas Gold and Silver Corporation Common Shares no par value nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Revolution Medicines Inc. Common Stock for 2 Days and Americas Gold and Silver Corporation Common Shares no par value for 0 Days on average.
| RVMD | USAS | |
|---|---|---|
Market Cap | $40.39B | $1.36B |
Volume | 2,941,009 | 3,177,621 |
Sector | Health | Basic Materials |
52-Week High | $221.15 | $10.03 |
52-Week Low | $49.56 | $3.59 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $37.09B | $1.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Revolution Medicines (RVMD) trades at $188.44, down 2.84% on the day, amid a bearish technical signal. The company reported no revenue in 2025, with a net loss of $1.13 billion, and has missed earnings expectations for three consecutive quarters. However, recent positive developments include the start of a Phase 3 trial for RASONQUE in pancreatic cancer and FDA Breakthrough Therapy Designation, fueling analyst optimism.
The outlook balances high-risk, high-reward potential. Strong analyst support (91.67% buy ratings) and a $253.35 consensus price target suggest significant upside, driven by the promising oncology pipeline. Key risks include substantial cash burn, lack of current revenue, and clinical trial execution uncertainties, making the stock suitable for investors comfortable with biotech volatility.
USAS trades at $4.02, down 4.29% on the day, reflecting ongoing volatility amid mixed operational performance. The company reported a net loss of $87.45M in 2025, though revenue is projected to grow to $182M in 2026 with a narrowing loss. Recent news highlights progress at its Galena and Cosalá mines, including high-grade silver discoveries and sustainability initiatives, signaling potential for future production growth.
The outlook is speculative, with high-risk turnaround potential driven by operational improvements and exposure to silver and critical minerals. Key risks include persistent negative profitability, high valuation multiples like EV/EBITDA of 455.68, and reliance on successful mine development. Analyst consensus is unanimously bullish, but investors must weigh execution risks against long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Revolution Medicines Inc. Common Stock
Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →About Americas Gold and Silver Corporation Common Shares no par value
Americas Gold and Silver Corporation is a Canada-based mining company that explores for and produces silver, along with by-product gold, copper, lead, and zinc. Its operating assets include the Galena Complex in Idaho and the Cosalá Operations in Sinaloa, Mexico.
Read more on USAS →
